Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth

Completed · Phase 1/Phase 2

Conditions studied: HIV Infections, Meningitis

In brief

Bacterial meningitis infection is common in youth 2 to 24 years of age in the United States. This disease can be treated by antibiotics, but mortality rates associated with meningitis of up to 53% have been estimated. Vaccination against meningitis may be effective in preventing this disease, especially for HIV-infected youth who have weakened immune systems. The purpose of this study was to determine the safety of and immune response to a preventive meningitis vaccine in HIV-infected youth.

Key facts

Study ID
NCT00459316
Run by
National Institute of Allergy and Infectious Diseases (NIAID)
People needed
384
Starts
2007-06-01
Expected to finish
2013-03-01
Last updated by the study team
2021-11-03

Who can join

Age: 2 and older, up to 24. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.